William Harris, MD
Medical Oncology · Seattle, WANPI 1508980194
Payments from drug & device makers
Across 474 payments — averaging $4255.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$744K
- AstraZeneca$263K
- Agios Pharmaceuticals, Inc.$209K
- Exelixis Inc.$181K
- Sanofi US Services Inc.$174K
- Halozyme Inc$126K
- plus $320K from 10 others
Across 1 payment — averaging $940.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$940
What the payments were for
- Consulting fees$17,97147%
- Speaking & faculty fees$15,75141%
- Travel & lodging$1,2213%
- Food & beverage$3,1228%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 129 | $744,067 |
| AstraZeneca | 9 | $262,632 |
| Agios Pharmaceuticals, Inc. | 66 | $208,760 |
| Exelixis Inc. | 43 | $181,428 |
| Sanofi US Services Inc. | 15 | $173,639 |
| Halozyme Inc | 162 | $126,240 |
| Astrazeneca UK Limited | 3 | $105,467 |
| E.r. Squibb & Sons, L.L.C. | 8 | $78,388 |
| Servier Bioinnovation | 2 | $63,423 |
| Boston Scientific | 23 | $40,618 |
| Eisai Inc. | 4 | $16,529 |
| Servier Pharmaceuticals LLC | 4 | $8,521 |
| Biocompatibles UK Ltd | 2 | $5,213 |
| Bard Peripheral Vascular, Inc. | 1 | $1,438 |
| Pfizer | 2 | $465 |
| Genentech USA, Inc. | 1 | $143 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)$11,167
- TheraSphere Y90 Glass Microspheres 10 GBq$5,865
- LENVIMA$4,183
- GENERAL PAIN MANAGEMENT$2,400
- TIBSOVO$1,971
- IMFINZI$731
- GENERAL ONCOLOGY$600
- TECENTRIQ$143
- PADCEV$135
How this compares
$2,016,970 in reported general payments places this provider in the 80th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 12 | $2,202 |
| Prochlorperazine Maleate | 25 | $561 |
| Ondansetron Hcl | 27 | $378 |
| LoperamideLoperamide Hcl | 18 | $239 |
| Dexamethasone | 23 | $119 |
| Amlodipine Besylate | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Seattle
- Michael SchweizerSeattle$27.4M
- Ajay GopalSeattle$14.6M
- Scott TykodiSeattle$14.2M
- Evan YuSeattle$9.8M
- Christina BaikSeattle$9M
- David MaloneySeattle$8.5M
- Shailender BhatiaSeattle$7.5M
- Andrew CovelerSeattle$7.1M
- Jennifer SpechtSeattle$6.4M
- Vivian OehlerSeattle$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.